Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK5 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AK5 small interfering RNA is a gene-silencing tool that utilizes the RNA interference (RNAi) pathway to specifically target and reduce the expression of Adenylate kinase 5 (AK5). AK5 is a phosphotransferase involved in maintaining adenine nucleotide homeostasis and has been identified as an independent genetic risk factor for Alzheimer's disease. Research indicates that silencing AK5 in microglial cells attenuates pro-inflammatory responses, such as the production of nitric oxide and tumor necrosis factor-alpha, while enhancing phagocytic activity and inducing metabolic reprogramming. While currently utilized primarily in research settings to investigate neuroinflammation and metabolic dysfunction, AK5-targeted siRNA represents a potential therapeutic strategy for the treatment or prevention of Alzheimer's disease.
- Other names
- AK5 siRNAAK-5 siRNAAK 5 siRNAadenylate kinase 5 siRNA
02
Targets
AK (Adenylate kinase isoenzyme 6)
Beyond the preview
Go deeper on AK5 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK5 small interfering RNA.